I think many can overcome cancer and live many more years if we help the patient learn how to deal with causes rather than just treat symptoms.
Useful information about treating cancer is coming out every day. Now they offer a far easier radiation approach described below in the WSJ. Please also review Alternative ways to treat Early Breast cancer from the WSJ here.
The outcomes are very similar and one way is far easier on the patient, do the entire radiation treatment in one day along with the surgery. You can see that, for example, they are looking at only a little over 1.5 % difference in the 5 year breast cancer recurrence rate between taking 3-6 weeks of the patients time traveling daily to the radiologist to get low dose repeated radiation vs intraoperative radiation all given in one visit, during the operation. This offers the convenience of not losing weeks from work. This clearly makes the single application of radiation very attractive to most patients and the 1.5 difference in recurrent rate is a tiny advantage for those who took the time to make all those visits to the radiation center.
So they did have a little lower “recurrence” rate but there were no deaths over 5 years in either group so recurrences are still clearly treatable.
Now if the patient were to call me for the second opinion, I like to go beyond just settling the issue re: which treatment(s) to select but remind people that we are all living longer than ever before. Since you have this issue now let us start to treat the underlying causes and with the levels of round- up and antibiotics now present in our water food and air I start to do something for each letter of F.I.G.H.T. so toxins are key but also low level chronic inflammation helps set the stage for most chronic degenerative diseases.
Thus with 30% of people properly tested for gluten sensitivity I want to RESTORE tight junctions. I do not find any probiotics are able to restore more than a few of the over 30 thousand different strains of healthy bacteria we all had once. Today most are well under 10,000 different stains so that is a key factor contributing to overgrowth of pathogens in our intestinal flora and that leads to more leaky gut and chronic inflammation. RESTORE is proven to restore tight junctions and lower inflammation.
Also I want to lower the load of toxins and so I like oral chelators, and high dose vitamin C acts, as a chelator when the C is exiting the body so I like patients to use the VitaChek C test, which shows them how much C is in their urine, with the admonition that the more C in their urine stick test, the better their long-term survival will be. That test is only available in 50 strip bulk boxes from TECO Diagnostics in Anaheim CA see tecodiag.com costing around $9 for the 50 tests.
In addition, I now have them add Zeogold caps or powder to that Vitamin C so that we are able to significantly enhance the detoxification process over just taking high dose oral vitamin C daily for life, which is a standard recommendation since I make for everyone, as I want all of us to be as sharp at age 90, as my mentor Linus Pauling was.
Therefore, every cancer consultation I do will restore tight junctions in their intestine using RESTORE and they all need 1 tsp containing 4 grams of BIOENERGY C two to four times every day of their lives. Then since not everyone can afford to also take my oral chelation product, BCI, which now stands for Binding Cellular Impurities, I at least want them on ZEOGOLD, one capsule or one scoopful depending on which form of Zeolite they select. That way I am addressing the organic toxins we are all carrying, as mentioned in my F.I.G.H.T. acronym. SEE Suzanne Somers excellent book TOX-SICK, which has my chapter explaining the effect toxins are having on hormones.
Sincerely,
Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
Alternative Way to Treat Early-Stage Breast Cancer With Radiation
A single-dose technique costs less than traditional radiation treatment but with a higher risk of recurrence
By
MELINDA BECK
Aug. 24, 2015 4:36 p.m. ET
Breast-cancer specialists are sharply divided over a new radiation technique that costs less and is more convenient than conventional therapy.
The technique, known as intraoperative radiation therapy, or IORT, involves administering a single dose of radiation at the same time a patient is having lumpectomy surgery to remove a tumor. A large, randomized controlled trial concluded that IORT has fewer side effects and appears to prevent the return of cancer nearly as well as traditional treatment, in which patients undergo radiation sessions five days a week for up to seven weeks.
Oncologists with opposing opinions have been debating that conclusion in letters and editorials in major medical journals, including the Lancet and BMJ. Some critics point out that the study found women who had IORT face twice the risk of a cancer recurrence compared with traditional radiation (3.3% versus 1.3% over five years).
Some also criticize the design of the IORT study and say patients haven’t been followed long enough to draw conclusions. “A lot of us are scratching our heads as to why [IORT] would be appropriate,” says David Wazer, chair of radiation oncology at Brown and Tufts medical schools and a vocal critic.
Yet proponents of IORT say the risk of recurrence with either radiation treatment over five years is tiny, and IORT’s advantages could outweigh the higher risk of recurrence for some patients.
“A lot of women who hear about this option make an informed decision to use it,” says Stephen Grobmyer, director of the breast center at the Cleveland Clinic, which is collecting data on nearly 1,000 patients who have had the treatment at 19 U.S. centers.
At many radiation centers, a big portion of revenue comes from delivering lengthy courses of treatment to breast-cancer patients. “Depending on your perspective, [moving to a single treatment during surgery] is either a significant threat or a quantum leap forward,” Anthony Zietman, editor in chief of the International Journal of Radiation Oncology, wrote in an editorial this month.
Radiation has revolutionized breast-cancer treatment since the 1980s, allowing older women with small, early-stage tumors to opt for lumpectomies rather than mastectomies. Survival rates are similar, because radiation helps destroy any stray cancer cells left behind. About 60% of the more than 200,000 women in the U.S. diagnosed annually with early-stage breast cancer undergo lumpectomy with radiation.
To date, however, only conventional, whole-breast external-beam radiation has a long record of safety and effectiveness, which is why some radiation oncologists say they are reluctant to abandon it.
Use of IORT for breast-cancer patients, with just a single radiation dose during surgery, started in Europe in the late 1990s. In 2000, developers of one method called targeted intraoperative radiotherapy, or TARGIT, organized a clinical trial to compare it with traditional radiation. They enrolled 3,451 women from 33 centers in 11 countries, including the U.S.; about half the participants received IORT and the rest got conventional therapy.
In a paper published in the Lancet last year, the investigators calculated that the five-year risk of cancer recurrence was 3.3% for the women who had IORT, compared with 1.3% for the control group—a margin that was within the trial’s predetermined definition of “non-inferiority.”